anti-tumor glycan monoclonal antibodies OmniAb/AvidiMab (Scancell/University of Nottingham)

N/A

Report date: 2025/01/26 18:32:54

Base Information

Drug Nameanti-tumor glycan monoclonal antibodies OmniAb/AvidiMab (Scancell/University of Nottingham)
Drug Alias NamemAbs targeting specific tumour-associated glycans OmniAb/AvidiMab (Scancell/University of Nottingham)glycolipid modulating fully human antibodies OmniAb (University of Nottingham)glycan-targeting mAbs (University of Nottingham)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionGlycolipid modulators
TargetsUpdating
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Nottingham
China Registration ClassN/A

Develop Information

Active CompaniesScancell LtdUniversity Of Nottingham
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A